MedTrace Logo

Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Allograft Nephropathy

NCT00659620 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-04-16

No results posted yet for this study

Summary

Mesenchymal Stem Cell (MSC) have been shown to have immunosuppressive and repairing properties. the investigators will infuse expanded MSC into patients who develop Chronic Allograft Nephropathy. The purpose of this study is to find out MSC is more effective in preventing organ rejection and maintaining kidney function.

Conditions

  • Kidney Transplant
  • Chronic Allograft Nephropathy

Interventions

BIOLOGICAL

mesenchymal stem cell

transplantation of mesenchymal stem cell

Sponsors & Collaborators

  • Fuzhou General Hospital

    lead OTHER

Principal Investigators

  • Jianming Tan T Jianming, professor · Fuzhou General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2008-05-31
Completion
2010-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659620 on ClinicalTrials.gov